Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06615414
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-15
Brief Title:
Cardiovascular Manifestations in Ph-negative MPN
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical and Subclinical Cardiovascular Manifestations in Philadelphia Negative Myeloproliferative Neoplasms
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary aim of this research is to investigate the clinical and subclinical cardiovascular complications and its relationship with myeloproliferative neoplasms seeking to assess incidence prevalence and severity in comparison to healthy group and analyze potential risk factors including genetic mutations inflammatory markers and hematological parameters
Detailed Description:
Myeloproliferative neoplasms MPNs are a group of hematological disorders characterized by clonal proliferation of stem cells leading to excessive production of blood cells The primary types include polycythemia vera essential thrombocythemia and primary myelofibrosis They share a common characteristic in that they lack the Philadelphia chromosome
Patients with MPN face an elevated risk of various clinical cardiovascular complications including arterial and venous thromboembolism hypertension and heart failure This increased risk can be attributed to several factors including chronic inflammation hyperviscosity due to increased blood cells count and genetic mutation like JAK2 V617F which plays a pivotal role in disease pathogenesis
While clinical cardiovascular events in MPN patients are well-documented subclinical manifestations such as subclinical atherosclerosis pulmonary hypertension left ventriclar hypertrophy diastolic dysfunction and arrhythmia are often overlooked These subclinical changes may significantly contribute to morbidity and mortality but are not routinely assessed in clinical practice Non invasive modalities such as electrocardiography echocardiography carotid doppler ultrasound and limb doppler ultrasound can provide vulnerable tools for early detection of these cardiovascular manifestations
So understanding the relationship between myloproliferative neoplasms and incidence and severity of cardiovascular complications is crucial This knowledge can enhance risk assessment improve patient care and outcomes and facilitate targeted interventions
Patients with MPN face an elevated risk of various clinical cardiovascular complications including arterial and venous thromboembolism hypertension and heart failure This increased risk can be attributed to several factors including chronic inflammation hyperviscosity due to increased blood cells count and genetic mutation like JAK2 V617F which plays a pivotal role in disease pathogenesis
While clinical cardiovascular events in MPN patients are well-documented subclinical manifestations such as subclinical atherosclerosis pulmonary hypertension left ventriclar hypertrophy diastolic dysfunction and arrhythmia are often overlooked These subclinical changes may significantly contribute to morbidity and mortality but are not routinely assessed in clinical practice Non invasive modalities such as electrocardiography echocardiography carotid doppler ultrasound and limb doppler ultrasound can provide vulnerable tools for early detection of these cardiovascular manifestations
So understanding the relationship between myloproliferative neoplasms and incidence and severity of cardiovascular complications is crucial This knowledge can enhance risk assessment improve patient care and outcomes and facilitate targeted interventions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None